Studies on selectin blocker. 9. SARs of non-sugar selectin blocker against E-, P-, L-selectin bindings

Hideki Moriyama, Yasuyuki Hiramatsu, Takao Kiyoi, Toshio Achiha, Yoshimasa Inoue, Hirosato Kondo

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

As a part of study of selectin blockers, we have already reported that a non-sugar selectin antagonist (3) was successfully discovered using a computational screening (Hiramatsu, Y.; Tsukida, T.; Nakai, Y.; Inou, Y.; Kondo, H.J. Med. Chem. 2000, 43, 1476). To investigate the SARs of compound 3 against E-, P-, and L-selectins, we synthesized the derivatives of compound 3 and evaluated their inhibitory activities toward selectin bindings. The structural diversity of compound 3 contained the following: (1) and modification of the spacer unit (4-7), (2) a modification of the tail (8-11), (3), a modification of the head unit (12-18). As a result, it was found that a non-sugar based selectin blocker (3) could be a potential lead compound for E-, P-, and L-selectin blockers and wome of the derivatives showed broad and/or selective inhibitory activities toward the E-, P-, and L-selectins. In addition, it was found that the experimental evidence well supported that the computational screening using 3D-pharmacophore model could be useful methodology to find out a new lead for the several type of selectin blockers, which included a broad and/or a selective inhibitor.

Original languageEnglish
Pages (from-to)1479-1491
Number of pages13
JournalBioorganic and Medicinal Chemistry
Volume9
Issue number6
DOIs
Publication statusPublished - Jan 1 2001
Externally publishedYes

Fingerprint

L-Selectin
Selectins
P-Selectin
Screening
Lead compounds
Derivatives
Head

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Pharmaceutical Science
  • Drug Discovery
  • Clinical Biochemistry
  • Organic Chemistry

Cite this

Studies on selectin blocker. 9. SARs of non-sugar selectin blocker against E-, P-, L-selectin bindings. / Moriyama, Hideki; Hiramatsu, Yasuyuki; Kiyoi, Takao; Achiha, Toshio; Inoue, Yoshimasa; Kondo, Hirosato.

In: Bioorganic and Medicinal Chemistry, Vol. 9, No. 6, 01.01.2001, p. 1479-1491.

Research output: Contribution to journalArticle

Moriyama, Hideki ; Hiramatsu, Yasuyuki ; Kiyoi, Takao ; Achiha, Toshio ; Inoue, Yoshimasa ; Kondo, Hirosato. / Studies on selectin blocker. 9. SARs of non-sugar selectin blocker against E-, P-, L-selectin bindings. In: Bioorganic and Medicinal Chemistry. 2001 ; Vol. 9, No. 6. pp. 1479-1491.
@article{75fb96510e04499289e0b9f3de755034,
title = "Studies on selectin blocker. 9. SARs of non-sugar selectin blocker against E-, P-, L-selectin bindings",
abstract = "As a part of study of selectin blockers, we have already reported that a non-sugar selectin antagonist (3) was successfully discovered using a computational screening (Hiramatsu, Y.; Tsukida, T.; Nakai, Y.; Inou, Y.; Kondo, H.J. Med. Chem. 2000, 43, 1476). To investigate the SARs of compound 3 against E-, P-, and L-selectins, we synthesized the derivatives of compound 3 and evaluated their inhibitory activities toward selectin bindings. The structural diversity of compound 3 contained the following: (1) and modification of the spacer unit (4-7), (2) a modification of the tail (8-11), (3), a modification of the head unit (12-18). As a result, it was found that a non-sugar based selectin blocker (3) could be a potential lead compound for E-, P-, and L-selectin blockers and wome of the derivatives showed broad and/or selective inhibitory activities toward the E-, P-, and L-selectins. In addition, it was found that the experimental evidence well supported that the computational screening using 3D-pharmacophore model could be useful methodology to find out a new lead for the several type of selectin blockers, which included a broad and/or a selective inhibitor.",
author = "Hideki Moriyama and Yasuyuki Hiramatsu and Takao Kiyoi and Toshio Achiha and Yoshimasa Inoue and Hirosato Kondo",
year = "2001",
month = "1",
day = "1",
doi = "10.1016/S0968-0896(01)00023-2",
language = "English",
volume = "9",
pages = "1479--1491",
journal = "Bioorganic and Medicinal Chemistry",
issn = "0968-0896",
publisher = "Elsevier Limited",
number = "6",

}

TY - JOUR

T1 - Studies on selectin blocker. 9. SARs of non-sugar selectin blocker against E-, P-, L-selectin bindings

AU - Moriyama, Hideki

AU - Hiramatsu, Yasuyuki

AU - Kiyoi, Takao

AU - Achiha, Toshio

AU - Inoue, Yoshimasa

AU - Kondo, Hirosato

PY - 2001/1/1

Y1 - 2001/1/1

N2 - As a part of study of selectin blockers, we have already reported that a non-sugar selectin antagonist (3) was successfully discovered using a computational screening (Hiramatsu, Y.; Tsukida, T.; Nakai, Y.; Inou, Y.; Kondo, H.J. Med. Chem. 2000, 43, 1476). To investigate the SARs of compound 3 against E-, P-, and L-selectins, we synthesized the derivatives of compound 3 and evaluated their inhibitory activities toward selectin bindings. The structural diversity of compound 3 contained the following: (1) and modification of the spacer unit (4-7), (2) a modification of the tail (8-11), (3), a modification of the head unit (12-18). As a result, it was found that a non-sugar based selectin blocker (3) could be a potential lead compound for E-, P-, and L-selectin blockers and wome of the derivatives showed broad and/or selective inhibitory activities toward the E-, P-, and L-selectins. In addition, it was found that the experimental evidence well supported that the computational screening using 3D-pharmacophore model could be useful methodology to find out a new lead for the several type of selectin blockers, which included a broad and/or a selective inhibitor.

AB - As a part of study of selectin blockers, we have already reported that a non-sugar selectin antagonist (3) was successfully discovered using a computational screening (Hiramatsu, Y.; Tsukida, T.; Nakai, Y.; Inou, Y.; Kondo, H.J. Med. Chem. 2000, 43, 1476). To investigate the SARs of compound 3 against E-, P-, and L-selectins, we synthesized the derivatives of compound 3 and evaluated their inhibitory activities toward selectin bindings. The structural diversity of compound 3 contained the following: (1) and modification of the spacer unit (4-7), (2) a modification of the tail (8-11), (3), a modification of the head unit (12-18). As a result, it was found that a non-sugar based selectin blocker (3) could be a potential lead compound for E-, P-, and L-selectin blockers and wome of the derivatives showed broad and/or selective inhibitory activities toward the E-, P-, and L-selectins. In addition, it was found that the experimental evidence well supported that the computational screening using 3D-pharmacophore model could be useful methodology to find out a new lead for the several type of selectin blockers, which included a broad and/or a selective inhibitor.

UR - http://www.scopus.com/inward/record.url?scp=0034933033&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034933033&partnerID=8YFLogxK

U2 - 10.1016/S0968-0896(01)00023-2

DO - 10.1016/S0968-0896(01)00023-2

M3 - Article

VL - 9

SP - 1479

EP - 1491

JO - Bioorganic and Medicinal Chemistry

JF - Bioorganic and Medicinal Chemistry

SN - 0968-0896

IS - 6

ER -